The tariff classification of Pulmozyme® (dornase alfa) Inhalation Solution; Raptiva® (Efalizumab) for injection, subcutaneous; Rituxan® (Rituximab); TNKase™ (Tenecteplase); and Xolair® (Omalizumab) for subcutaneous use
Reasoning
The tariff classification of Pulmozyme® (dornase alfa) Inhalation Solution; Raptiva® (Efalizumab) for injection, subcutaneous; Rituxan® (Rituximab); TNKase™ (Tenecteplase); and Xolair® (Omalizumab) for subcutaneous use
Cite this ruling
CBP Ruling K83806 (3004909115): The tariff classification of Pulmozyme® (dornase alfa) Inhalation Solution; Raptiva® (Efalizumab) for injection, subcutaneous; Rituxan® (Rituximab); TNKase™ (Tenecteplase); and Xolair® (Omalizumab) for subcutaneous use
Paste this into a product's override reason when citing this ruling as justification for a classification.
Other rulings for HS6 300490
The tariff classification of FLOXIN® Otic (ofloxacin otic solution) 0.3%, imported put up in plastic multiple-dose bottles, from Finland
The tariff classification of Genasense™ (oblimersen sodium), imported put up in single-use 10 mL glass vials for IV infusion, from Germany
The tariff classification of MLN518, imported in bulk and measured-dose forms, for use in Phase 1 clinical trials, from the United Kingdom and Canada
The tariff classification of ZYMAR™ (gatifloxacin ophthalmic solution) 0.3%
The tariff classification of Anti-Itch Cream (Item No. 0053), Acne Treatment Cream (Item No. 0054), Hemorrhoidal Ointment (Item No. 0056), Oral Pain Relief Ointment (Item No. 0057) and Muscle & Joint Pain Relief Gel (Item No. 0059) over-the-counter medicaments, from Korea